Alnylam Slides as Investors Focus on Softer AMVUTTRA Momentum Despite Strong Q3 Results

Alnylam Pharmaceuticals (ALNY) is down 15.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied less to the headline quarter and more to investor concerns about the pace of growth in Alnylam’s key TTR franchise, especially AMVUTTRA. While third-quarter revenue and earnings were strong, management signaled that full-year TTR sales are expected near the low end of guidance and discussed slower-than-hoped conversion of physician interest into patient demand.

Details:

Alnylam reported third-quarter 2026 total revenue of about $1.46 billion, up 17% year over year, while total net product revenue rose 52% to roughly $1.29 billion.

AMVUTTRA generated about $1.13 billion in quarterly revenue, making it the main growth driver, but investors appear to be reacting to concerns about the launch trajectory rather than the reported number itself.

Full-year 2026 guidance was reiterated, but the company indicated TTR product sales should land near the low end of its stated range, which can signal softer momentum than some investors expected.

On the earnings call, management also pointed to slower conversion from expanded physician engagement into demand growth and cited an expected effect from more restrictive first-line Medicare Advantage access following a UnitedHealth policy change effective October 1.

Sources:

Alnylam, Nasdaq, Earnings Whispers

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ALNY Insider Trading Activity

$ALNY insiders have traded $ALNY stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

DAVID E I PYOTT has made 0 purchases and 5 sales selling 3,830 shares for an estimated $1,145,852.
BRYAN SUPRAN (EVP, CLO and Secretary) sold 1,758 shares for an estimated $398,855

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ALNY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ALNY Hedge Fund Activity

We have seen 401 institutional investors add shares of $ALNY stock to their portfolio, and 358 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 4,490,826 shares (+390.0%) to their portfolio in Q2 2026, for an estimated $1,351,873,350
JPMORGAN CHASE & CO added 2,675,517 shares (+inf%) to their portfolio in Q2 2026, for an estimated $805,410,882
INVESCO LTD. added 2,462,592 shares (+190.6%) to their portfolio in Q2 2026, for an estimated $741,314,069
MARSHALL WACE, LLP removed 839,519 shares (-76.4%) from their portfolio in Q2 2026, for an estimated $252,720,404
DEEP TRACK CAPITAL, LP added 825,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $248,349,749
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 755,377 shares (+inf%) to their portfolio in Q2 2026, for an estimated $227,391,138
D. E. SHAW & CO., INC. added 659,616 shares (+148.4%) to their portfolio in Q2 2026, for an estimated $198,564,204

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ALNY Congressional Stock Trading

Members of Congress have traded $ALNY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by members of Congress over the last 6 months:

SENATOR CORY A. BOOKER sold up to $15,000 on 08/11.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ALNY Analyst Ratings

Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 06/29/2026

To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.

$ALNY Price Targets

Multiple analysts have issued price targets for $ALNY recently. We have seen 2 analysts offer price targets for $ALNY in the last 6 months, with a median target of $425.0.

Here are some recent targets:

Patrick R. Trucchio from HC Wainwright & Co. set a target price of $470.0 on 06/29/2026
Eric Joseph from Citigroup set a target price of $380.0 on 05/19/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.